Poll Results

December 2019 Question of the Month

How likely are payers to focus on formulary placement or exclusion for unapproved products (i.e. medical foods)?

Somewhat likely for exclusion purposes only: 72%

No change in focus from today: 14%

Unlikely: 14%

Highly likely: 0%

November 2019 Question of the Month

 The new Fair and Accurate Medicaid Pricing Act excludes Authorized Generics (AG) from AMP calculations for brand manufacturers, likely increasing their AMP prices and subsequent rebates. How will this change effect brand manufacturers decision to launch an AG or not?
Brand manufacturer will reconsider when to launch the AG and only launch after an ANDA is approved: 100%
Brand manufacturer will launch the AG before the ANDA is introduced in the market: 0%
The Act will not impact brand manufacturers’ decisions to launch AGs: 0%
Brand manufacturers will not launch AG’s any longer: 0%

October 2019 Question of the Month

Biosimilars have gotten off to a slow start in the marketplace. What change will most dramatically affect the adoption rate?

PBM Formulary and coverage decisions: 83%

New Legislation: 17%

HHS/CMS Policy Changes: 0%

September 2019 Question of the Month

Who will be the slowest to adopt the electronic real-time benefit check?

Physicians: 53.8%

PBMs: 30.8%

EMRs: 15.4%

Surescripts: 0%

August 2019 Question of the Month

If the NADAC survey of pharmacy costs becomes mandatory, how will this impact the NADAC and Medicaid pharmacy reimbursement?

NADAC would decrease, resulting in lower Medicaid reimbursements to pharmacies:  88%

NADAC would not change and Medicaid reimbursements would remain the same:  12%

NADAC would increase, resulting in higher Medicaid reimbursements to pharmacies:  0%


July 2019 Question of the Month

What percent of new drugs in the next 5 years will use alternative payment models like subscription plans or multi-year payment plans?


0%:   0%

1% to 5%:   82%

5% to 10%:   9%

10% to 20%:   9%

20% to 30%:   0%

June 2019 Question of the Month

How quickly will payer and EHR real time benefit checks be implemented?

6 months:  0%

1 year:  0%

2 years:  75.0%

3 years:  12.5%

4 years or more:  12.5%

Never:  0%

May 2019 Question of the Month

HHS has proposed altering the safe harbor for pharmaceutical rebates. When will the proposed POS rebates be implemented for Medicare Part D and Medicaid plans?

2020:  27.27%

2021:  9.09%

2022:  9.09%

2023:  18.18%

Never:  36.36%

April 2019 Question of the Month

CVS and Walgreens have announced they will carry CBD products in select states. How soon until we see CBD products in all retail chain pharmacies?

0-6 months: 23.08%

6-12 months: 30.77%

12-24 months: 30.77%

24+ months: 0.00%

Never: 15.38%

March 2019 Question of the Month

How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule: 50%

Lower net costs after the implementation of the proposed rule: 12.5%

No impact, net costs will be at the same levels as today: 37.5%